RxDoctor Payments Data

Catherine Kilby, MD

Internal Medicine · Anchorage, AKNPI 1356356802

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 44 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 18 manufacturers reported payments, led by AstraZeneca at 29.4% of the total. Reporting peaked in 2021 at $199 and has fallen 61.5% since, to $77 in 2025.

$856in general payments, 2019–2025

Across 44 payments — averaging $19.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$252
  • AbbVie$195
  • Lilly USA, LLC$59
  • Eisai Inc.$53
  • Novo Nordisk$46
  • Biohaven Pharmaceuticals, Inc.$40
  • plus $211 from 12 others

What the payments were for

  • Food & beverage$856100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$856 in reported general payments places this provider in the 75th percentile of 124 internal medicine providers in Alaska.

See all internal medicine providers in Alaska

Medicare billing

Part B allowed, 2024
$242,067
Medicare patients
308
Services billed
3,037

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide44$67,339
EliquisApixaban44$67,274
JardianceEmpagliflozin43$66,091
Trelegy ElliptaFluticasone/Umeclidin/Vilanter19$24,878
FarxigaDapagliflozin Propanediol14$19,607
JanuviaSitagliptin Phosphate16$17,738
MyrbetriqMirabegron17$15,506
Insulin Lispro Kwikpen U-100Insulin Lispro17$7,305
Fluticasone-SalmeterolFluticasone Propion/Salmeterol34$5,744
SynthroidLevothyroxine Sodium51$5,400
Pravastatin Sodium204$5,049
Lantus SolostarInsulin Glargine,hum.Rec.Anlog25$4,269
Estradiol27$3,399
Atorvastatin Calcium241$3,304
Levothyroxine Sodium204$3,112

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Paxlovid$23$70,09055 claims
Novo NordiskOzempic$46$67,33944 claims
GSKTrelegy Ellipta$14$24,87819 claims
AstraZenecaFarxiga$252$19,60714 claims
AbbVieSynthroid$195$5,40051 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 124 internal medicine providers in Alaska.

Other internal medicine in Anchorage

See the full list for Alaska

Where these figures come from

Is this you, or does something look wrong? →